Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Yvette Drew

Newcastle AuthorsTitleYearFull text
Dr Asima Mukhopadhyay
Dr Yvette Drew
Liz Matheson
Dr Mo Salehan
Lucy Gentles
et al.
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors2019
Lucy Gentles
Bojidar Goranov
Elizabeth Matheson
Dr Ashleigh Herriott
Dr Angelika Kaufmann
et al.
Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types2019
Dr Yvette Drew
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in gremlin BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)2018
Lucy Gentles
Liz Matheson
Dr Nicholas Bown
Alice Bradbury
Maryam Zanjirband Zanjirband
et al.
Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor2018
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.
Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
Dr Yvette Drew
A phase I-II study of the oral PARP inhibitor Rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumours2017
Dr Miranda Patterson
Dr Yvette Drew
Professor Nicola Curtin
PARP2017
Dr Stuart Rundle
Alice Bradbury
Dr Yvette Drew
Professor Nicola Curtin
Targeting the ATR-CHK1 Axis in Cancer Therapy2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr Yvette Drew
Homologous recombination deficiency and ovarian cancer2016
1234